ArriVent BioPharma, Inc.
AVBP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AVBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AVBP
ArriVent BioPharma, Inc. is a clinical-stage biotechnology company focused on developing differentiated therapies for cancer, with its lead product candidate firmonertinib and an early-stage candidate ARR-217, and has not yet generated any product revenue.
Key risk: No approved products or revenue
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.49B
Cash Runway
27.9 moLead Asset
ARR-002 (Phase 1)
Next Catalyst
Phase3_Topline · Feb 15, 2028Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 6 clinical trials · 3 catalysts for ArriVent BioPharma, Inc..
ArriVent BioPharma, Inc. is a clinical-stage biotechnology company focused on developing differentiated therapies for cancer, with its lead product candidate firmonertinib and an early-stage candidate ARR-217, and has not yet generated any product revenue.
- Lead product candidate is firmonertinib, a potential treatment for certain cancers [sec_mda · as of 2026-08-12].
- As of June 30, 2026, the company reported cash and equivalents of $154.7M and a net loss of -$49.9M for the quarter [sec].
- The company has an accumulated deficit of $369.1 million as of September 30, 2025 [sec_mda · as of 2025-11-10].
- ArriVent dosed the first patient in a Phase 1 study for ARR-217 in March 2026, in partnership with Lepu [sec_mda · as of 2026-08-12].
- The company expects to continue incurring losses and anticipates these will increase as it advances its pipeline through clinical trials and regulatory processes [sec_mda · as of 2026-08-12].
What works
- ArriVent has a lead candidate, firmonertinib, advancing through clinical trials, indicating a focused pipeline [sec_mda · as of 2026-08-12].
- The company has initiated a Phase 1 study for a second candidate, ARR-217, expanding its pipeline beyond the lead asset [sec_mda · as of 2026-08-12].
- As of June 30, 2026, the company held $154.7M in cash and equivalents, providing a runway to support ongoing operations [sec].
What to weigh
- ArriVent has no approved products and has not generated any revenue from product sales [sec_mda · as of 2026-08-12].
- The company has a significant accumulated deficit of $369.1 million as of September 30, 2025, reflecting ongoing losses [sec_mda · as of 2025-11-10].
- ArriVent expects net losses to increase substantially as it advances its product candidates through clinical trials and seeks regulatory approvals [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
The company has no approved products and no product revenue.
“We do not have any products approved for sale and have not generated any revenue from product sales or otherwise.”
SEC MD&A · August 12, 2026
The company has an accumulated deficit of $369.1 million as of September 30, 2025.
“As of September 30, 2025, we had an accumulated deficit of $369.1 million.”
SEC MD&A · November 10, 2025
First patient dosed in Phase 1 study for ARR-217 in March 2026.
“In March 2026, we dosed our first patient in the ongoing Phase 1 study in partnership with Lepu.”
SEC MD&A · August 12, 2026
Catalyst timeline
- 2028-02-15 · Phase3_Topline — Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety — Topline results from a pivotal Phase 3 study of firmonertinib are expected, which could inform regulatory filing plans.
- 2030-12-01 · Phase3_Topline — Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of — Another Phase 3 topline readout is anticipated, though the specific candidate is not specified in the available data.
- 2032-04-30 · Phase3_Topline — Phase 3 Topline: A Global Phase 3, Double-Blind, Randomized, Controlled Multicenter Study to Assess the Efficacy and — A third Phase 3 topline readout is scheduled, representing a longer-term catalyst for the pipeline.
Risks & what to watch (3)›
Key risks
- No approved products or revenue — The company has no products approved for sale and has not generated any product revenue, relying solely on external funding [sec_mda · as of 2026-08-12].
- Significant accumulated deficit — Accumulated deficit of $369.1 million as of September 30, 2025, reflecting sustained operating losses [sec_mda · as of 2025-11-10].
- Clinical and regulatory uncertainty — Future capital needs depend on trial progress, regulatory outcomes, and manufacturing costs, which are uncertain [sec_mda · as of 2026-08-12].
What to watch
- Topline data from the Phase 3 study of firmonertinib, expected around February 2028 [catalyst].
- Progress of the Phase 1 study for ARR-217 in solid tumors, with first patient dosed in March 2026 [sec_mda · as of 2026-08-12].
- Cash runway and burn rate, given the $154.7M cash position as of June 30, 2026 and expected increasing losses [sec].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run ArriVent BioPharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ArriVent BioPharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
27.9 months
D/E 0.08 · 0% dilution
Lead: Phase 3
4 candidates
3 upcoming, next in ~534d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
138
Total value held
$954.2M
| Holder | Shares | Value |
|---|---|---|
| suvretta capital management, llc | 4,401,083 | $101.5M |
| infinitum asset management, llc | 4,148,923 | $95.7M |
| hhlr advisors, ltd. | 3,929,117 | $90.6M |
| vanguard capital management llc | 3,057,786 | $70.5M |
| orbimed advisors llc | 3,027,328 | $69.8M |
| fmr llc | 3,016,132 | $69.6M |
| blackrock, inc. | 2,530,301 | $58.4M |
| novo holdings a/s | 1,942,142 | $44.8M |
| vivo capital, llc | 1,771,832 | $40.9M |
| general catalyst group management, llc | 1,494,786 | $34.5M |
Showing top 10 of 138 institutional holders of ArriVent BioPharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 16.3%
- Days to cover
- 14.0
- Shares short
- 7,109,751
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AVBP short interestGovernance
Frequently asked questions
What is the AI investment thesis for ArriVent BioPharma, Inc.?
ArriVent BioPharma, Inc. is a clinical-stage biotechnology company focused on developing differentiated therapies for cancer, with its lead product candidate firmonertinib and an early-stage candidate ARR-217, and has not yet generated any product revenue.
What is ArriVent BioPharma, Inc.'s lead drug candidate?
ArriVent BioPharma, Inc.'s most advanced tracked candidate is ARR-002 (Phase 1) for Ovarian Cancer.
What is ArriVent BioPharma, Inc.'s next catalyst?
ArriVent BioPharma, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety " — expected February 15, 2028.
Who is the CEO of ArriVent BioPharma, Inc.?
Dr. Zhengbin Yao Ph.D. is the chief executive officer of ArriVent BioPharma, Inc. (AVBP).
Where is ArriVent BioPharma, Inc. headquartered?
ArriVent BioPharma, Inc. (AVBP) is headquartered in Newtown Square, PA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.